Aerie Pharmaceuticals, Inc.

activities was relatively low, $22.4 million, and we had $218.4 million in cash, cash equivalents, and investments as of September 30, 2020. The net cash used in operating activities of $22.4 million was better than the second quarter equivalent of $22.9 million, reflecting continued progress in containing operating expenses. Let me emphasize an important point. We used about $22 million of cash in the third quarter, and we ended the quarter with $218 million of cash. The additional $15 million from the Santan licensing agreement obviously further bolsters our cash position. Consider also that the burden of funding the Phase III trials in Japan for OPRESA and ROCLATAN is materially reduced, and prospects for future collaborations are on the rise. With that, and ongoing revenue growth, we have a substantial cash runway. And I'm going to say this slowly. There is no current need, nor desire, nor plan to raise equity capital. Finally, shares outstanding at quarter end total 46.8 million. For additional information regarding our third quarter results and prior period comparisons, please refer to today's earnings release in our form 10Q which we expect to file tomorrow. Now, I would like to turn the call over to Jerome for questions. Jerome?

Thank you. At this time, I would like to remind everyone, in order to ask a question, please press star 1 on your telephone keypad. Your first question comes from the line of Ken Kashuturi from Cohen & Company. Your line is now open.

Thanks so much, Rich. I think you said it even slow enough for someone not as smart as me to understand, so thanks for clarifying that. On ROCLA-10, just wondering, guys, if you can talk about further work on managed care for Part D. I know we have pretty good coverage. Just wondering if we can expand it, and when do you think we will be able to? And then a second question is around what you hear from the clinicians in terms of hyperemia. From time to time on clinician checks, it comes up. Wondering if you could put this into some perspective, in terms of what type of retention rates, which I think would be the best way to monitor this, what type of retention rates do you see in Prostaglandins, other Prostaglandins, and can you compare that to Repressa and Roclatan in terms of the retention rates that we're seeing here from a refill level? I think that would probably cut through the clutter a little bit of the hyperemia issue. Thanks so much.